Toronto Dominion Bank reduced its stake in shares of The Clorox Company (NYSE:CLX - Free Report) by 16.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 54,767 shares of the company's stock after selling 10,977 shares during the period. Toronto Dominion Bank's holdings in Clorox were worth $8,895,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Brooklyn Investment Group raised its position in shares of Clorox by 163.8% during the fourth quarter. Brooklyn Investment Group now owns 153 shares of the company's stock worth $25,000 after acquiring an additional 95 shares during the last quarter. Redwood Park Advisors LLC acquired a new stake in Clorox during the 4th quarter valued at approximately $26,000. Millstone Evans Group LLC bought a new position in Clorox during the 4th quarter worth approximately $31,000. Asset Planning Inc bought a new position in Clorox during the 4th quarter worth approximately $32,000. Finally, GKV Capital Management Co. Inc. acquired a new position in shares of Clorox in the 4th quarter worth approximately $32,000. 78.53% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of brokerages recently weighed in on CLX. JPMorgan Chase & Co. lowered their target price on shares of Clorox from $151.00 to $144.00 and set a "neutral" rating for the company in a research note on Tuesday, May 6th. Evercore ISI set a $140.00 price objective on Clorox and gave the stock an "underperform" rating in a research report on Tuesday, May 6th. Morgan Stanley dropped their price objective on Clorox from $165.00 to $150.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Citigroup decreased their target price on Clorox from $165.00 to $150.00 and set a "neutral" rating for the company in a research note on Monday, April 14th. Finally, UBS Group dropped their price target on Clorox from $176.00 to $154.00 and set a "neutral" rating on the stock in a research note on Thursday, April 17th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $151.23.
View Our Latest Stock Analysis on Clorox
Insider Transactions at Clorox
In other Clorox news, Director Pierre R. Breber purchased 4,000 shares of the company's stock in a transaction that occurred on Wednesday, May 7th. The shares were acquired at an average price of $136.57 per share, with a total value of $546,280.00. Following the transaction, the director now owns 4,000 shares in the company, valued at $546,280. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.57% of the stock is currently owned by insiders.
Clorox Stock Up 0.0%
Clorox stock traded up $0.07 during mid-day trading on Monday, reaching $130.97. The stock had a trading volume of 1,243,078 shares, compared to its average volume of 1,333,942. The firm has a market capitalization of $16.14 billion, a PE ratio of 35.78, a price-to-earnings-growth ratio of 2.62 and a beta of 0.60. The Clorox Company has a fifty-two week low of $127.60 and a fifty-two week high of $171.37. The stock's 50-day simple moving average is $139.64 and its 200-day simple moving average is $152.24. The company has a debt-to-equity ratio of 20.52, a quick ratio of 0.60 and a current ratio of 0.94.
Clorox (NYSE:CLX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.12). The business had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. Clorox had a net margin of 6.38% and a return on equity of 316.87%. The business's revenue for the quarter was down 8.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.71 EPS. On average, sell-side analysts forecast that The Clorox Company will post 7.15 EPS for the current fiscal year.
Clorox Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 9th. Stockholders of record on Wednesday, April 23rd were issued a dividend of $1.22 per share. This represents a $4.88 dividend on an annualized basis and a dividend yield of 3.73%. The ex-dividend date was Wednesday, April 23rd. Clorox's dividend payout ratio is currently 87.61%.
Clorox Profile
(
Free Report)
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.
Featured Stories
Before you consider Clorox, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clorox wasn't on the list.
While Clorox currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
